Cardiol Therapeutics Files 6-K with Financials
Ticker: CRDL · Form: 6-K · Filed: Aug 12, 2024 · CIK: 1702123
Sentiment: neutral
Topics: financials, sec-filing, 6-k
TL;DR
Cardiol Therapeutics dropped Q2 2024 financials in a 6-K filing.
AI Summary
Cardiol Therapeutics Inc. filed a 6-K report on August 12, 2024, for the period ending June 30, 2024. The filing includes condensed interim consolidated financial statements and management's discussion and analysis for the three and six months ended June 30, 2024. The company is based in Oakville, Ontario, Canada.
Why It Matters
This filing provides investors with updated financial statements and management's perspective on the company's performance for the second quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant financial changes.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Filer of the 6-K report
- June 30, 2024 (date) — End of the reporting period for financial statements
- August 12, 2024 (date) — Filing date of the 6-K report
- Oakville, Ontario, Canada (location) — Company's principal executive offices
FAQ
What period do the financial statements in the 6-K cover?
The financial statements cover the three and six months ended June 30, 2024.
When was this 6-K report filed?
The report was filed on August 12, 2024.
What are the main documents included in this filing?
The filing includes Exhibit 99.1, Condensed Interim Consolidated Financial Statements, and Exhibit 99.2, Management's Discussion and Analysis.
Where is Cardiol Therapeutics Inc. located?
The company's principal executive offices are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada.
Is Cardiol Therapeutics filing a Form 20-F or 40-F?
The filing indicates that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 231 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2024-08-12 17:00:21
Filing Documents
- tm2420157d1_6k.htm (6-K) — 11KB
- tm2420157d1_ex99-1.htm (EX-99.1) — 363KB
- tm2420157d1_ex99-2.htm (EX-99.2) — 311KB
- tm2420157d1_ex99-3.htm (EX-99.3) — 11KB
- tm2420157d1_ex99-4.htm (EX-99.4) — 12KB
- tm2420157d1_ex99-2img001.jpg (GRAPHIC) — 7KB
- tm2422148d1_ex99-1sp1img001.jpg (GRAPHIC) — 9KB
- 0001104659-24-088416.txt ( ) — 732KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: August 12, 2024 By: /s/ Chris Waddick Name: Chris Waddick Title: Chief Financial Officer